Elan has reported a 17 per cent rise in revenues for the first quarter of the year.
Revenues at the firm that focuses on neurological disorders totalled $288.4 million in the three months, Elan said.
Revenue from its multiple sclerosis drug Tysabri totalled $288.2 million, which was just ahead of expectations according to Bloomberg News.
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
Get basic
*New subscribers only
You can cancel any time.
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
You can cancel any time.
Team Pass
Get a Business Account for you and your team